最高法院驳回特朗普政府限制跨性别囚犯部分医疗待遇的诉求


2026年10月21日 / 美国东部时间上午11:35 / 哥伦比亚广播公司新闻

华盛顿——美国最高法院周三维持下级法院判决,驳回特朗普政府此前试图强制执行的一项新的监狱管理局政策,该政策本将终止针对跨性别囚犯的部分医疗干预措施。

最高法院以无署名的单行命令形式驳回了司法部提出的紧急上诉,该上诉请求最高法院暂停地区法院的禁令并恢复新规定的效力。这项新政策将停止为已被或将被诊断为性别烦躁症的囚犯提供手术和激素治疗,以及社会适应支持。

大法官塞缪尔·阿利托和克拉伦斯·托马斯表示,他们本会允许特朗普政府强制执行这项政策变更。

特朗普政府于上月向最高法院提起诉讼,要求介入这一纠纷,并辩称针对跨性别囚犯的新政策有必要“维护机构安全”。

但挑战这项规定的联邦监狱中一名跨性别女性和两名跨性别男性的律师表示,自1992年以来,监狱管理局一直在为患有性别烦躁症的囚犯提供激素治疗。他们称,这项新政策将导致该局监管下的近1000名囚犯终止治疗。

最高法院审理的这起纠纷源于囚犯们去年代表被诊断为性别烦躁症的在押人员对特朗普政府提起的诉讼。诉讼提起的背景是特朗普总统发布行政令,禁止使用联邦资金为监狱管理局监管下的跨性别囚犯提供医疗程序或治疗。

作为对特朗普指令的回应,监狱管理局于2月发布新政策,表示将不再提供用于治疗性别烦躁症的手术或激素治疗。正在接受激素治疗的囚犯将被纳入逐步减量计划,最终完全停止相关干预措施。

根据新规定,监狱管理局还将不再为患有性别烦躁症的囚犯提供任何社会适应支持,例如乳房垫、束胸衣、假发和化妆品。

在伴随该政策发布的一份备忘录中,监狱管理局援引了特朗普的行政令,并表示其修改规则是为了“反映与最新科学信息更一致的性别烦躁症治疗方案,符合监狱管理局长期以来提供针对囚犯独特需求的医疗护理的政策,并考虑到惩教环境中复杂的安全和管理问题”。

今年6月,美国地区法官罗伊斯·兰伯思发布命令,禁止特朗普政府强制执行2月的政策。该法官要求监狱管理局继续为患有性别烦躁症的在押人员群体提供医疗干预措施和社会适应支持。

“本法庭并未介入针对跨性别群体的文化战争,”由罗纳德·里根总统任命的兰伯思在一份31页的判决书中写道,“法庭只是认定,政府在发布限制向被诊断为性别烦躁症的囚犯提供性别确认护理的新政策时,违反了联邦法律。”

兰伯思在8月发布了继续阻止该政策实施的命令。

随后,美国哥伦比亚特区巡回上诉法院的一个三人合议庭拒绝解除地区法院的禁令。在以2比1作出的判决中,上诉法院表示,监狱管理局“未充分考虑其在先前政策下提供性别确认护理的自身经验”,也未能有力证明其在案件实质问题上有可能胜诉。

在向最高法院提起的紧急上诉中,副检察长D.约翰·佐尔辩称,地区法院的判决“在广泛范围内阻止了执行政府选定的政策”。

佐尔为终止跨性别囚犯医疗待遇的政策的合法性进行辩护,并表示监狱管理局“在认定此类干预措施并非医疗必需,以及认定安全和监狱管理问题有充分理由改变政策时,都适时考虑了其先前的经验”。

但反对政府新规定的人士辩称,特朗普政府未提供任何证据表明监狱管理局的医疗保健提供者认为目前受限的医疗治疗是有效、无效还是有害的。

“监狱管理局终止了其医疗保健提供者数十年来一直推荐的治疗,取而代之的是心理治疗——其自身专家承认,没有证据表明心理治疗可有效治疗性别烦躁症——以及精神药物——监狱管理局的医疗总监甚至没有声称该药物可治疗性别烦躁症,仅能治疗共病,”跨性别囚犯的律师写道。

他们还辩称,该机构并未“指出任何一起与为性别烦躁症提供医疗干预相关的安全事件”。

“如果监狱管理局的医生认为这种治疗对患者无益或有害,或者该机构认定该治疗损害了安全,那么监狱管理局肯定会在行政记录中提及此事,”原告律师表示,“这一明显的疏漏,以及其决定的不合理性,清楚表明这些理由是为了支撑特朗普总统在行政令中提出的要求而编造的。”

https://www.cbsnews.com/video/justice-alito-supreme-court-not-part-political-movement/

最高法院大法官阿利托:“我们不属于任何政治运动”

(时长01:05)

Supreme Court rejects Trump bid to restrict some medical treatments for transgender inmates

October 21, 2026 / 11:35 AM EDT / CBS News

Washington — The Supreme Court on Wednesday left intact a lower court decision that blocked the Trump administration from enforcing a new Bureau of Prisons policy that would end certain medical interventions for transgender inmates.

In an unsigned, one-line order, the high court rejected an emergency appeal from the Justice Department asking it to freeze the district court order and revive the new rules. The policy would cut off surgical and hormone therapy treatments, as well as social accommodations, for inmates who have been or will be diagnosed with gender dysphoria.

Justices Samuel Alito and Clarence Thomas said they would have allowed the Trump administration to enforce the change.

The Trump administration sought the Supreme Court’s intervention in the dispute last month and argued that the new policy for transgender inmates is needed to “maintain institutional security.”

But lawyers for a transgender woman and two transgender men in federal prisons who challenged the rules said the Bureau of Prisons has provided hormone treatment to people with gender dysphoria since 1992. They said that the new policy required the end of treatment for nearly 1,000 inmates in the bureau’s custody.

The dispute before the Supreme Court stems from a lawsuit the inmates filed against the Trump administration last year on behalf of incarcerated people diagnosed with gender dysphoria. The suit was filed after President Trump issued an executive order that barred the use of federal funds for medical procedures or treatments for transgender inmates who are in Bureau of Prisons custody.

In response to Mr. Trump’s directive, the Bureau of Prisons issued a new policy in February stating that it would not provide surgeries or hormone therapy to address gender dysphoria. Inmates who were receiving hormone treatments could be put on a tapering plan that would eventually lead to a discontinuation of the interventions.

Under the new rules, the Bureau of Prisons will also no longer provide any social accommodations, such as breast padding, binders, wigs and makeup, to inmates with gender dysphoria.

In a memo accompanying the policy, the Bureau of Prisons cited Mr. Trump’s executive order and said it changed its rules to “reflect treatment for gender dysphoria that is more aligned with the latest scientific information, that is consistent with BOP’s longstanding policy of providing medical care that is tailored to the unique needs of the inmate, and that accounts for the complex security and administration concerns in the correctional environment.”

In June, U.S. District Judge Royce Lamberth issued an order preventing the Trump administration from enforcing the February policy. The judge required the Bureau of Prisons to continue providing medical interventions and social accommodations to a class of inmates with gender dysphoria.

“The court does not wade into the culture war being waged against transgender individuals,” Lamberth, who was appointed by President Ronald Reagan, wrote in a 31-page decision. “The court simply concludes that the government violated [federal law] when it issued a new policy restricting the provision of gender-affirming care to inmates diagnosed with gender dysphoria.”

Lamberth issued an order in August that continued to block the policy.

A three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit then declined to lift the district court’s injunction. In a 2-1 decision, the appeals court said the Bureau of Prisons “did not adequately consider its own experience providing gender-affirming care under its prior policy” and failed to make a strong showing that it is likely to succeed on the merits of the case.

In its emergency appeal to the Supreme Court, Solicitor General D. John Sauer argued that the district court’s decision “prevents the application of the Executive’s chosen policy” on a broad basis.

Sauer defended the legality of the policy ending medical treatments for transgender inmates and said the Bureau of Prisons “seasonably considered its prior experience both in determining that such interventions are not medically necessary and in determining that security and prison-administration concerns independently justified a change in policy.”

But the challengers of the administration’s new rules argued the Trump administration failed to put forth any evidence indicating whether healthcare providers for the Bureau of Prisons found the now-restricted medical treatments to be effective, ineffective or harmful.

“BOP cut off treatment that its healthcare providers had recommended for decades and replaced it with psychotherapy — which its own expert acknowledges is backed by no evidence demonstrating its efficacy as a treatment for gender dysphoria — and psychotropic medications — which BOP’s Medical Director does not even claim treat gender dysphoria, only co-existing conditions,” lawyers for the transgender inmates wrote.

They also argued that the agency has not “pointed to a single security incident” relating to the provision of medical interventions to address gender dysphoria.

“Had BOP’s doctors found this treatment unhelpful or harmful to patients or had the agency found that the treatment compromised security, surely BOP would have mentioned it in the administrative record,” lawyers for the plaintiffs said. “That glaring omission, as well as the unreasonableness of its decision, make it clear that the rationales were contrived to support the demand President Trump made in the EO.”

https://www.cbsnews.com/video/justice-alito-supreme-court-not-part-political-movement/

Justice Alito on the Supreme Court: “We are not part of any political movement”

(01:05)

评论

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注

湘ICP备2026001899号-2